CNSX:VEXT - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	62	N/A	7	7	3
12/31/2024	38	N/A	4	-1	4
6/30/2024	33	-7	-1	0	N/A
3/31/2024	34	-2	2	4	N/A
12/31/2023	35	4	2	4	N/A
9/30/2023	35	5	4	6	N/A
6/30/2023	34	7	0	5	N/A
3/31/2023	34	9	-2	3	N/A
12/31/2022	35	11	-3	6	N/A
9/30/2022	37	6	-3	8	N/A
6/30/2022	38	6	0	11	N/A
3/31/2022	39	6	-10	12	N/A
12/31/2021	37	5	-8	11	N/A
9/30/2021	34	5	-9	8	N/A
6/30/2021	33	5	-8	8	N/A
3/31/2021	30	4	2	6	N/A
12/31/2020	25	2	-1	3	N/A
9/30/2020	22	0	-2	2	N/A
6/30/2020	20	0	-6	1	N/A
3/31/2020	20	0	-6	0	N/A
12/31/2019	22	3	-6	0	N/A
9/30/2019	23	4	-5	-1	N/A
6/30/2019	23	5	-3	-1	N/A
3/31/2019	21	4	-1	0	N/A
12/31/2018	18	4	1	2	N/A
12/31/2017	15	4	N/A	2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: VEXTの予測収益成長が貯蓄率 ( 2.1% ) を上回っているかどうかを判断するにはデータが不十分です。

収益対市場: VEXTの収益がCanadian市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です

高成長収益: VEXTの収益が今後 3 年間で大幅に増加すると予想されるかどうかを判断するにはデータが不十分です。

収益対市場: VEXTの収益 ( 34.5% ) Canadian市場 ( 6.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: VEXTの収益 ( 34.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: VEXTの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Vext Science 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Price target increased by 12% to CA$0.75

Price target increased by 7.2% to CA$1.30

Price target decreased to CA$1.24

Price target decreased to CA$1.46

Price target decreased to CA$1.84

Price target decreased to CA$1.99

Recent updates

Second quarter 2024 earnings released: US$0.018 loss per share (vs US$0.004 profit in 2Q 2023)

Vext Science, Inc. to Report Q2, 2024 Results on Aug 20, 2024

Price target increased by 12% to CA$0.75

Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper

Chief Financial Officer recently bought CA$63k worth of stock

Vext Science, Inc. to Report Q1, 2024 Results on May 29, 2024

New minor risk - Earnings quality

Vext Science, Inc. to Report Q4, 2023 Results on Apr 25, 2024

New major risk - Shareholder dilution

Vext Science, Inc. Announces Transition of Jason Thai Nguyen Out of Executive Role

There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Vext Science, Inc. to Report Q3, 2023 Results on Nov 28, 2023

Vext Science, Inc., Annual General Meeting, Dec 15, 2023

New major risk - Shareholder dilution

Vext Science, Inc. announced that it has received $11.5 million in funding from LLF Financial S.A.

Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?

Second quarter 2023 earnings: EPS exceeds analyst expectations

Vext Science, Inc. to Report Q2, 2023 Results on Aug 23, 2023

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Vext Science, Inc. Resigns Stephan Bankosz as Corporate Secretary, Effective August 25, 2023

First quarter 2023 earnings released: EPS: US$0 (vs US$0.016 in 1Q 2022)

Vext Science, Inc. to Report Q1, 2023 Results on May 25, 2023

Price target increased by 7.2% to CA$1.30

Full year 2022 earnings released: EPS: US$0.079 (vs US$0.036 in FY 2021)

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Less than half of directors are independent

Vext Science, Inc. (CNSX:VEXT) entered into agreement to acquire Appalachian Pharm Processing, LLC for $12.5 million.

Vext Science, Inc. Announces Board Changes

Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now

Price target decreased to CA$1.24

Third quarter 2022 earnings released: EPS: US$0.003 (vs US$0.007 in 3Q 2021)

Less than half of directors are independent

Vext Science, Inc. to Report Q3, 2022 Results on Nov 17, 2022

Price target decreased to CA$1.46

Vext Science, Inc., Annual General Meeting, Dec 15, 2022

We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt

Vext Science Announces Filing of Provisional Patent Application

Sopica Special Opportunities Fund Limited, managed by LLF Financial S.A. acquired a 13.65% stake in Vext Science, Inc. (CNSX:VEXT) from Jason T. Nguyen for $3 million.

Second quarter 2022 earnings released: EPS: US$0.014 (vs US$0.013 in 2Q 2021)

Director recently bought CA$53k worth of stock

Vext Science, Inc. to Report Q2, 2022 Results on Aug 24, 2022

Vext Science, Inc. Announces CFO Transition

First quarter 2022 earnings released

Vext Science, Inc. to Report Q1, 2022 Results on May 30, 2022

Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly

Price target decreased to CA$1.84

Less than half of directors are independent

Full year 2021 earnings released: EPS: US$0.036 (vs US$0.023 in FY 2020)

Vext Science, Inc. Announces Executive Changes

Vext Science, Inc. to Report Q4, 2021 Results on Apr 20, 2022

Price target decreased to CA$1.99

Less than half of directors are independent

Vext Science, Inc. Appoints Mark W. Opzoomer as Board of Director

Third quarter 2021 earnings released

Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?

Second quarter 2021 earnings released

Is Vext Science (CSE:VEXT) A Risky Investment?

Vext Science, Inc. (CNSX:VEXT) completed the acquisition of a 72,000 square foot industrial facility in Eloy, Arizona.

First quarter 2021 earnings released

Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)

Full year 2020 earnings released

Vext Science, Inc. Announces CFO Changes

New 90-day high: CA$1.54

Vext Science, Inc. has completed a Composite Units Offering in the amount of CAD 18.032 million.

Vext Science, Inc. announced that it has received CAD 1.5624 million in funding

Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?

New 90-day high: CA$1.13

New 90-day high: CA$0.95